Abstract
Neuroinflammation, characterized by microglial activation and overexpression of the 18-kDa translocator protein (TSPO), is a hallmark of Alzheimer's disease (AD). This study optimized the synthesis of the second-generation PET tracer $[^{18}F]DPA714$ and utilized it to dynamically monitor neuroinflammation in the APP/PS1 mouse model across various ages (6–16 months). Results demonstrated that significant microglial activation emerges at 12–13 months, correlating strongly with histological markers. These findings highlight the potential of $[^{18}F]DPA714$ PET imaging for identifying optimal therapeutic windows for anti-inflammatory interventions in AD.
Introduction
Alzheimer's disease (AD) pathogenesis involves not only amyloid-beta plaques and tau tangles but also a robust neuroinflammatory response driven by microglia, the brain's immune cells. Monitoring this activation is essential for understanding disease progression and evaluating treatments. TSPO is a validated biomarker for microglial activation, but early tracers like $[^{11}C]PK11195$ suffer from short half-lives and high non-specific binding. $[^{18}F]DPA714$ offers improved specificity and a longer half-life, yet its longitudinal performance in AD models required further validation and synthesis optimization.
Methods
Radiochemistry Optimization
The synthesis of $[^{18}F]DPA714$ was optimized by varying precursor dosage, temperature, and reaction time. The crude mixture was purified using semi-preparative reversed-phase HPLC to ensure high radiochemical purity.
Longitudinal Imaging and Validation
APP/PS1 and Wild-type (Wt) mice were scanned using micro-PET at 6–7, 9–10, 12–13, and 15–16 months. PET images were co-registered with MRI templates to analyze Volumes of Interest (VOIs) in the cortex and hippocampus. Tracer specificity was confirmed via blocking studies with the TSPO antagonist PK11195, and PET signals were correlated with Iba-1 and TSPO immunofluorescence staining.
Results
Synthesis and Purity
Optimal radiochemical yield (42.3 ± 5.1%, non-decay corrected) was achieved using 2 mg of precursor dissolved in 300 µl acetonitrile at 105°C for 10 minutes.
The final product exhibited exceptional radiochemical purity (99.9%), as confirmed by radio-HPLC analysis, which showed a single sharp peak corresponding to the tracer.
Longitudinal Monitoring
No significant differences in tracer uptake were observed between AD and control groups at 6–10 months. However, at 12–13 months, APP/PS1 mice showed significantly higher uptake in the cortex (2.77 ± 0.13 vs. 1.93 ± 0.32, p = 0.0014) and hippocampus (3.33 ± 0.10 vs. 2.10 ± 0.35, p = 0.0008) compared to controls. This elevation persisted into the 15–16 month bracket.
Discussion and Conclusion
The study identifies a critical "flare-up" point for neuroinflammation at approximately 12 months in the APP/PS1 model. The high correlation between PET signal and histology ($r^2$ between 0.76 and 0.88) validates $[^{18}F]DPA714$ as a reliable tool for tracking microglial density. While human application must account for TSPO genetic polymorphisms, this optimized mouse protocol provides a robust framework for testing anti-inflammatory drug efficacy in preclinical stages.
$[^{18}F]DPA714$ PET imaging effectively monitors the dynamic progression of neuroinflammation in AD models. By pinpointing the onset of significant microglial activation, this approach facilitates the identification of optimal timing for anti-inflammatory therapies.
Summary updated